BR112022013620A2 - Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos - Google Patents

Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos

Info

Publication number
BR112022013620A2
BR112022013620A2 BR112022013620A BR112022013620A BR112022013620A2 BR 112022013620 A2 BR112022013620 A2 BR 112022013620A2 BR 112022013620 A BR112022013620 A BR 112022013620A BR 112022013620 A BR112022013620 A BR 112022013620A BR 112022013620 A2 BR112022013620 A2 BR 112022013620A2
Authority
BR
Brazil
Prior art keywords
glycoprotein
methods
adenoviral vectors
vectors encoding
viral antigens
Prior art date
Application number
BR112022013620A
Other languages
English (en)
Inventor
Cj Ertl Hildegund
Stephen Magowan Colin
Original Assignee
Virion Therapeutics Llc
The Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virion Therapeutics Llc, The Wistar Inst filed Critical Virion Therapeutics Llc
Publication of BR112022013620A2 publication Critical patent/BR112022013620A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

VETORES ADENOVIRAIS QUE CODIFICAM ANTÍGENOS VIRAIS DA HEPATITE B FUNDIDOS À GLICOPROTEÍNA D DO VÍRUS DO HERPES E MÉTODOS DE USO DOS MESMOS. São fornecidas neste documento variantes de ocorrência não natural da proteína Central do vírus da hepatite B (HBV), o domínio N-terminal da polimerase HBV e o domínio C-terminal da polimerase HBV, bem como os fragmentos imunogênicos dos mesmos. As proteínas de fusão compreendendo as variantes de HBV fundidas a uma sequência de glicoproteína (gD) do vírus herpes simplex (HSV), bem como métodos de uso das proteínas de fusão, também são fornecidas.
BR112022013620A 2020-01-09 2021-01-08 Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos BR112022013620A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062958827P 2020-01-09 2020-01-09
US202062958809P 2020-01-09 2020-01-09
US202062967104P 2020-01-29 2020-01-29
US202062967242P 2020-01-29 2020-01-29
US202063064571P 2020-08-12 2020-08-12
US202063064506P 2020-08-12 2020-08-12
US202063112202P 2020-11-11 2020-11-11
US202063112219P 2020-11-11 2020-11-11
PCT/US2021/012630 WO2021142212A1 (en) 2020-01-09 2021-01-08 Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same

Publications (1)

Publication Number Publication Date
BR112022013620A2 true BR112022013620A2 (pt) 2022-09-13

Family

ID=74505354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013620A BR112022013620A2 (pt) 2020-01-09 2021-01-08 Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos

Country Status (11)

Country Link
US (4) US20230063089A1 (pt)
EP (1) EP4087605A1 (pt)
JP (1) JP2023510544A (pt)
KR (1) KR20220163354A (pt)
CN (1) CN115335076A (pt)
AU (1) AU2021205936A1 (pt)
BR (1) BR112022013620A2 (pt)
CA (1) CA3166989A1 (pt)
IL (1) IL294387A (pt)
MX (1) MX2022008572A (pt)
WO (1) WO2021142212A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34956B1 (fr) * 2011-02-12 2014-03-01 Globeimmune Inc Therapeutique a base de levure pour infection chronique par l'hepatite b
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
CN109804075A (zh) 2016-08-01 2019-05-24 威斯塔解剖学和生物学研究所 用于疫苗应用的复制缺陷型腺病毒载体的组合物和方法

Also Published As

Publication number Publication date
WO2021142212A1 (en) 2021-07-15
US11291716B2 (en) 2022-04-05
CA3166989A1 (en) 2021-07-15
US20240091347A1 (en) 2024-03-21
AU2021205936A1 (en) 2022-07-21
US11850282B2 (en) 2023-12-26
IL294387A (en) 2022-08-01
KR20220163354A (ko) 2022-12-09
MX2022008572A (es) 2022-09-23
EP4087605A1 (en) 2022-11-16
CN115335076A (zh) 2022-11-11
US20210393770A1 (en) 2021-12-23
US20230063089A1 (en) 2023-03-02
JP2023510544A (ja) 2023-03-14
US20220175913A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
CO2021013878A2 (es) Vectores de virus adenoasociado recombinantes
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
CL2020002960A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
AR056138A1 (es) Procedimiento para la expresion recombinante de un polipeptido
DK11789A (da) Rekombinante vaccinia-vira
DK0596979T3 (da) Rekombinante nucleinsyrer fra plantevirus
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
BR112022011099A2 (pt) Tratamento de doenças relacionadas ao vírus da hepatite b
MX2021015465A (es) Vacuna para fiebre porcina africana.
ES2150416T3 (es) Vacuna virica defectiva producida por una linea celular complementada en trans.
ES2061708T3 (es) Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus.
CY1105680T1 (el) Μολυσματικος κλωνος cdna βορειοαμερικανικου ιου χοιρειου αναπαραγωγικου και αναπνευστικου συνδρομου (prrs) και χρησεις αυτου
AR046415A1 (es) Mimeticuerpos de nucleo de bisagra epo- mimeticos humanos, composiciones, metodos y usos
BRPI0518146A (pt) kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
FI3445397T3 (fi) Integraalisen membraaniproteiinin näyttö poxviruksen solunulkoisilla vaipallisilla virioneilla
ES2102815T3 (es) Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih.
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
MX2024004297A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
MX2022014943A (es) Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
ES2058486T3 (es) Inmunogenos nativos y recombinantes del grupo b de eimeria tenella utiles como vacunas para las coccidiosis.
BR112022013620A2 (pt) Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos
AR051853A1 (es) Vacuna para aumentar el crecimiento basada en epitopes neutralizantes